Loading...
Loading...
Ranked by Compass Score · 20 companies · Updated June 10, 2026
Biotech and genomics attract a specific type of investor excitement, the kind where a clinical trial readout or a CRISPR headline sends money flooding into the same five names every cycle. That crowding is the problem. The stocks everyone already knows about have already priced in the optimism, and you are essentially paying for a coin flip on a binary event with someone else's margin of safety baked in.
The Compass Score cuts through that by weighing eight factors simultaneously: pipeline depth, balance sheet runway, revenue trajectory, competitive position, valuation relative to peers, management track record, regulatory progress, and macro sensitivity. No single factor dominates. What comes out the other end is a ranked view of where genuine risk-reward sits, which is rarely where the herd is currently camped. The table below is ordered by that score. Work from the top down.
Get our top Biotech & Genomics ideas, free
The Alexandria e-letter delivers our highest-conviction picks, earnings intelligence, and contrarian calls twice a week. Join free.
Free forever. Unsubscribe anytime. We never share your email.
Higher Compass Scores reflect where fundamentals, momentum, and forward catalysts align. Tap any company for the full breakdown.
Standout: Market Position (86/100) · Direction: Accumulate · $30.2B
Standout: Market Position (97/100) · Direction: Accumulate · $1.02T
Standout: Revenue Growth (98/100) · Direction: Accumulate · $3.7B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $6.0B
Standout: Theme Purity (99/100) · Direction: Accumulate · $39.7B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $3.1B
Standout: Momentum (89/100) · Direction: Accumulate · $3.5B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $2.3B
Standout: Momentum (86/100) · Direction: Accumulate · $9.1B
Standout: Theme Purity (99/100) · Direction: Hold · $4.0B
Standout: Revenue Growth (86/100) · Direction: Accumulate · $8.5B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $7.6B
Standout: Theme Purity (99/100) · Direction: Accumulate · $5.1B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $5.0B
Standout: Profitability (90/100) · Direction: Accumulate · $2.0B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $2.7B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $4.7B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $1.3B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $947M
Standout: Revenue Growth (98/100) · Direction: Accumulate · $1.4B
By Alexandria's Compass Score, DexCom Inc. (NASDAQ:DXCM) currently ranks highest among Biotech & Genomics names with a score of 91/100 (True North). Compass Scores are recomputed weekly across eight factors, so rankings shift as the fundamentals do.
Every company is scored 1-100 on eight weighted factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The composite is percentile-normalized into a Compass Score and a tier from True North to Avoid. It is a contrarian lens that rewards what the crowd overlooks rather than what is already priced in.
A high Compass Score reflects where fundamentals, momentum, and forward catalysts align. It is research, not investment advice. Use the ranking as a starting point, then read each company's full Compass Direction analysis before making any decision.
Get the contrarian edge, free
Join the Alexandria e-letter for top-rated stocks, earnings intelligence, and the take the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Compass Scores are proprietary editorial research generated by Alexandria's analysis engine from publicly available data. They are one data point among many and do not constitute investment advice or a recommendation regarding any security. Rankings update weekly and may change.